» Articles » PMID: 36761777

TRAF6 Controls T Cell Homeostasis by Maintaining the Equilibrium of MALT1 Scaffolding and Protease Functions

Overview
Journal Front Immunol
Date 2023 Feb 10
PMID 36761777
Authors
Affiliations
Soon will be listed here.
Abstract

MALT1 is a core component of the CARD11-BCL10-MALT1 (CBM) signalosome, in which it acts as a scaffold and a protease to bridge T cell receptor (TCR) ligation to immune activation. As a scaffold, MALT1 binds to TRAF6, and T cell-specific TRAF6 ablation or destruction of MALT1-TRAF6 interaction provokes activation of conventional T (Tconv) effector cells. In contrast, MALT1 protease activity controls the development and suppressive function of regulatory T (Treg) cells in a T cell-intrinsic manner. Thus, complete loss of TRAF6 or selective inactivation of MALT1 catalytic function in mice skews the immune system towards autoimmune inflammation, but distinct mechanisms are responsible for these immune disorders. Here we demonstrate that TRAF6 deletion or MALT1 paracaspase inactivation are highly interdependent in causing the distinct immune pathologies. We crossed mice with T cell-specific TRAF6 ablation (-ΔT) and mice with a mutation rendering the MALT1 paracaspase dead in T cells ( PD-T) to yield -ΔT; PD-T double mutant mice. These mice reveal that the autoimmune inflammation caused by TRAF6-ablation relies strictly on the function of the MALT1 protease to drive the activation of Tconv cells. Vice versa, despite the complete loss of Treg cells in -ΔT; PD-T double mutant mice, inactivation of the MALT1 protease is unable to cause autoinflammation, because the Tconv effector cells are not activated in the absence of TRAF6. Consequentially, combined MALT1 paracaspase inactivation and TRAF6 deficiency in T cells mirrors the immunodeficiency seen upon T cell-specific MALT1 ablation.

Citing Articles

Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy.

Wu K, Li S, Hong G, Dong H, Tang T, Liu H Clin Transl Med. 2024; 14(11):e70089.

PMID: 39568154 PMC: 11578931. DOI: 10.1002/ctm2.70089.


Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy.

Zhou Z, Xu J, Liu S, Lv Y, Zhang R, Zhou X Biomark Res. 2024; 12(1):97.

PMID: 39227959 PMC: 11373505. DOI: 10.1186/s40364-024-00630-9.


Insights into mechanisms of MALT1 allostery from NMR and AlphaFold dynamic analyses.

Wallerstein J, Han X, Levkovets M, Lesovoy D, Malmodin D, Mirabello C Commun Biol. 2024; 7(1):868.

PMID: 39014105 PMC: 11252132. DOI: 10.1038/s42003-024-06558-y.


MALT1 substrate cleavage: what is it good for?.

Moud B, Ober F, ONeill T, Krappmann D Front Immunol. 2024; 15:1412347.

PMID: 38863711 PMC: 11165066. DOI: 10.3389/fimmu.2024.1412347.

References
1.
Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A . TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999; 13(8):1015-24. PMC: 316636. DOI: 10.1101/gad.13.8.1015. View

2.
Gewies A, Gorka O, Bergmann H, Pechloff K, Petermann F, Jeltsch K . Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep. 2014; 9(4):1292-305. DOI: 10.1016/j.celrep.2014.10.044. View

3.
Schubert D, Bode C, Kenefeck R, Hou T, Wing J, Kennedy A . Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014; 20(12):1410-1416. PMC: 4668597. DOI: 10.1038/nm.3746. View

4.
Grinberg-Bleyer Y, Oh H, Desrichard A, Bhatt D, Caron R, Chan T . NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 2017; 170(6):1096-1108.e13. PMC: 5633372. DOI: 10.1016/j.cell.2017.08.004. View

5.
Sun L, Deng L, Ea C, Xia Z, Chen Z . The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004; 14(3):289-301. DOI: 10.1016/s1097-2765(04)00236-9. View